Literature DB >> 22460909

Fibrinogen as a hemostatic agent.

Benny Sørensen1, Ole Halfdan Larsen, Catherine J Rea, Mariann Tang, Jonathan H Foley, Christian Fenger-Eriksen.   

Abstract

Coagulation factor I (fibrinogen) plays an essential role in the hemostatic system by bridging activated platelets and being the key substrate for thrombin in establishing a consolidating fibrin network. Fibrinogen is synthesized in the liver and the plasma concentration is 1 to 5-4.0 g/L. During recent 10 years, fibrinogen has been recognized to play an important role in controlling hemorrhage. Dilutional coagulopathy induced by colloid plasma expanders is characterized by fibrinogen deficiency and dysfunctional fibrin polymerization. Trauma and use of extracorporeal circulation is also known to reduce levels of fibrinogen. A series of laboratory experiments and experimental animal studies have suggested fibrinogen as a potent hemostatic agent. These data are supported by retrospective surveys as well as a series of prospective proof of principal clinical trials. This article provides a description of the biochemistry and mechanisms of fibrinogen as well as the etiology for developing fibrinogen deficiency. Furthermore, it summarizes laboratory and experimental data on the role of fibrinogen in dilutional coagulopathy and addresses laboratory monitoring issues. Finally, it lists retrospective and prospective studies, which have been designed to assess the clinical efficacy and safety of hemostatic intervention with fibrinogen concentrate. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460909     DOI: 10.1055/s-0032-1309287

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

Review 1.  Bleeding During Veno-Venous ECMO: Prevention and Treatment.

Authors:  Johannes Kalbhenn; Barbara Zieger
Journal:  Front Med (Lausanne)       Date:  2022-05-23

2.  Coagulopathy and Traumatic Brain Injury: Overview of New Diagnostic and Therapeutic Strategies.

Authors:  Ryuta Nakae; Yasuo Murai; Akio Morita; Shoji Yokobori
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-04-22       Impact factor: 2.036

3.  Association between plasma fibrinogen levels and mortality in acute-on-chronic hepatitis B liver failure.

Authors:  Zhexin Shao; Ying Zhao; Limin Feng; Guofang Feng; Juanwen Zhang; Jie Zhang
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

Review 4.  Pathophysiology of trauma-induced coagulopathy: disseminated intravascular coagulation with the fibrinolytic phenotype.

Authors:  Mineji Hayakawa
Journal:  J Intensive Care       Date:  2017-01-31

5.  Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study.

Authors:  Jostein S Hagemo; Simon Stanworth; Nicole P Juffermans; Karim Brohi; Mitchell Cohen; Pär I Johansson; Jo Røislien; Torsten Eken; Paal A Næss; Christine Gaarder
Journal:  Crit Care       Date:  2014-03-26       Impact factor: 9.097

6.  Fibrinogen and base excess levels as predictive markers of the need for massive blood transfusion after blunt trauma.

Authors:  Takehiro Umemura; Yoshihiko Nakamura; Takeshi Nishida; Kota Hoshino; Hiroyasu Ishikura
Journal:  Surg Today       Date:  2015-11-03       Impact factor: 2.549

7.  Recovery of fibrinogen concentrate after intraosseous application is equivalent to the intravenous route in a porcine model of hemodilution.

Authors:  Christoph J Schlimp; Cristina Solomon; Claudia Keibl; Johannes Zipperle; Sylvia Nürnberger; Wolfgang Ohlinger; Heinz Redl; Herbert Schöchl
Journal:  J Trauma Acute Care Surg       Date:  2014-05       Impact factor: 3.313

8.  Impact of fibrinogen level on the prognosis of patients with traumatic brain injury: a single-center analysis of 2570 patients.

Authors:  Ke Lv; Qiang Yuan; Pengfei Fu; Gang Wu; Xing Wu; Zhuoying Du; Jian Yu; Zhiqi Li; Jin Hu
Journal:  World J Emerg Surg       Date:  2020-09-25       Impact factor: 5.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.